Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methylprednisolone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 8/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 0.79 |
| ▸ | F2 | P00734 | 1/20 | 0.79 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.70 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL6 | P05231 | 1/20 | 0.70 |
| ▸ | GLUL | P15104 | 1/20 | 0.70 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.70 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylprednisolone SCHEMBL16221544 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL5084 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL7160264 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL143076 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL5085 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL12440040 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL13046609 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL13300483 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL21145528 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 | |
| Methylprednisolone SCHEMBL193216 | 1.00 | HIF1A (1.00) | HIF1APGRNR3C1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250009778-A1 | KRAS ANTAGONISTS | TRUETIVA INC (US) | 2025-01-09 | — | — | US | claimed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | claimed |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-04-09 | — | — | US | claimed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | claimed |
| US-20230173295-A1 | Systems, Devices, and Methods for Gamma Entrainment using Sensory Stimuli to Alleviate Cognitive Deficits and/or Neuroinflammation Induced by Chemotherapy Agents | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-08 | — | — | US | claimed |
| WO-2023055904-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2023-04-06 | — | — | WO | claimed |
| US-20220117990-A1 | KRAS ANTAGONISTS | TRUETIVA, Inc. (US) | 2022-04-21 | — | — | US | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | TERRESTRIAL BIO, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | MARENGO THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | FOUNDATION MEDICINE, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-2414377-A1 | NOVEL DERIVATIVES OF STEROIDALÝ3,2-C¨PYRAZOLE COMPOUNDS WITH GLUCOCORTICOID ACTIVITY | AstraZeneca AB (SE) | 2012-02-08 | — | — | EP | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010114476-A1 | NOVEL DERIVATIVES OF STEROIDAL[3,2-C]PYRAZOLE COMPOUNDS WITH GLUCOCORTICOID ACTIVITY | ASTRAZENECA AB (SE) | 2010-10-07 | — | — | WO | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | THE MCLEAN HOSPITAL CORPORATION (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636250-B2 | Microneedle array patches (MAPs), systems, and methods for manufacturing and using same | GLP1R, NPY1R, NPY4R | NR3C1 1020/4885HIF1A 2120/4885PGR 320/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | NR3C1 4788/4885HIF1A 1894/4885PGR 3943/4885 |
| US-20250009778-A1 | KRAS ANTAGONISTS | KRAS, NRAS, HRAS | NR3C1 3629/4885HIF1A 2407/4885PGR 3936/4885 |
| US-20100056488-A1 | CORTICOSTEROID CONJUGATES AND USES THEREOF | NR3C1, NR3C2, C3AR1 | NR3C1 1/4885HIF1A 4459/4885PGR 515/4885 |
| US-20260139051-A1 | COMBINATION THERAPIES USING MOLECULES BINDING TO TCR | CD2, CD4, CD47 | NR3C1 3637/4885HIF1A 4400/4885PGR 1961/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | NR3C1 3/4885HIF1A 4786/4885PGR 1161/4885 |
| US-20220117990-A1 | KRAS ANTAGONISTS | KRAS, NRAS, HRAS | NR3C1 3629/4885HIF1A 2407/4885PGR 3936/4885 |
| US-20260132471-A1 | GENOMIC BIOMARKERS OF EARLY RECURRENCE IN COLORECTAL CANCER (CRC) | MSH2, MSH6, PMS2 | NR3C1 2404/4885HIF1A 1498/4885PGR 2108/4885 |
| US-11952353-B2 | STAT3 transcription factor inhibitors and methods of using the same | STAT3, STAT1, STAT5A | NR3C1 309/4885HIF1A 252/4885PGR 1892/4885 |
| US-20260124222-A1 | ISOTHIAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL6B | NR3C1 41/4885HIF1A 292/4885PGR 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.